1560642-41-2

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 1208007-67-3 (S)-tert-butyl 2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1208009-37-3 (S)-2-(6-(4,4,5,5-tetramethyl-1,3,2-dioxapentane-2-yl)-1H-benzo[d]imidazole -2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 60725-19-1 (S)-2-((methoxycarbonyl)amino)-2-phenylacetic acid 

Downstream Products

• 1560642-43-4 C₅₀H₅₃N₇O₅ 
• 1560649-09-3 C₅₂H₅₆N₈O₆ 

Relevant academic research and scientific papers

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.